ArriVent BioPharma Inc. C...
(AVBP)
undefined
undefined%
At close: undefined
26.72
0.49%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors.
The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002.
It has strategic collaborations with Aarvik Therapeutics Inc.
The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
ArriVent BioPharma Inc. Common Stock
| Country | United States |
| IPO Date | Jan 26, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Dr. Zhengbin Yao Ph.D. |
Contact Details
Address: 18 Campus Boulevard Newtown Square, United States | |
| Website | https://www.arrivent.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US04272N1028 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Zhengbin Yao Ph.D. | Co-Founder, Chairman, President & Chief Executive Officer |
| Robin LaChapelle M.A. | Co-Founder & Chief Operating Officer |
| Winston Kung M.B.A. | Chief Financial Officer & Treasurer |
| Yang Wang Ph.D. | Chief Technology Officer |
| Dr. Stuart Lutzker M.D., Ph.D. | Co-Founder, President of Research & Development and Director |
| James Paul Kastenmayer J.D., Ph.D. | General Counsel & Secretary |
| Meghna Chowdary | Senior Vice President of Commercial Strategy |